P Impicciatore1, I Choonara. 1. Academic Division of Child Health, (University of Nottingham), Derbyshire Children's Hospital, Derby, UK.
Abstract
AIMS: To evaluate the activity of the European Medicines Evaluation Agency with regard to the registration for paediatric use of new medicines granted a marketing authorization. METHODS: European Public Assessment Reports published on the Internet from January 95 until April 98 have been analysed using the browser Microsoft Explorer and the software Adobe Acrobat Reader. RESULTS: Of the 45 new substances licensed since January 95, 29 (64%) were of possible use in children but only 10 were licensed for paediatric use. For the 19 drugs of possible use in children, but not approved for such a use, in nine instances (47%) their summary of product characteristics reported that their use in children has not been established. CONCLUSIONS: A change of practice by pharmaceutical companies and regulatory authorities is imperative so that children are not precluded from having the same rights to medicines as adults.
AIMS: To evaluate the activity of the European Medicines Evaluation Agency with regard to the registration for paediatric use of new medicines granted a marketing authorization. METHODS: European Public Assessment Reports published on the Internet from January 95 until April 98 have been analysed using the browser Microsoft Explorer and the software Adobe Acrobat Reader. RESULTS: Of the 45 new substances licensed since January 95, 29 (64%) were of possible use in children but only 10 were licensed for paediatric use. For the 19 drugs of possible use in children, but not approved for such a use, in nine instances (47%) their summary of product characteristics reported that their use in children has not been established. CONCLUSIONS: A change of practice by pharmaceutical companies and regulatory authorities is imperative so that children are not precluded from having the same rights to medicines as adults.
Authors: Suzie Ekins-Daukes; Peter J Helms; Colin R Simpson; Michael W Taylor; James S McLay Journal: Eur J Clin Pharmacol Date: 2004-05-14 Impact factor: 2.953
Authors: A Ceci; M Felisi; P Baiardi; F Bonifazi; M Catapano; C Giaquinto; A Nicolosi; M Sturkenboom; A Neubert; I Wong Journal: Eur J Clin Pharmacol Date: 2006-10-05 Impact factor: 2.953
Authors: Johanna Lindkvist; Marja Airaksinen; Ann Marie Kaukonen; Timo Klaukka; Kalle Hoppu Journal: Br J Clin Pharmacol Date: 2011-06 Impact factor: 4.335